Praxis Precision Medicines, Inc. (PRAX) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-02-19
How it makes money
It generates no current revenue, targeting future profits from clinical-stage candidates like ulixacaltamide and relutrigine that have reached the NDA submission stage.
The business operates as a pre-revenue biopharmaceutical developer focusing on neuronal excitation-inhibition imbalances. It translates genetic insights from epilepsy into precision medicines for both rare and prevalent central nervous system disorders.
Profitability depends entirely on the transition from clinical development to commercialization. The company has moved two programs—ulixacaltamide for essential tremor and relutrigine for developmental and epileptic encephalopathies—to the New Drug Application submission stage with the FDA.
What protects it: the moat
It protects its development pipeline through its proprietary Cerebrum small molecule and Solidus antisense oligonucleotide platforms which utilize computational tools and translational animal models.
The company maintains proprietary platforms to discover and develop first- and best-in-class therapies. Cerebrum utilizes computational tools to develop orally available small molecules, while Solidus is a computational engine for antisense oligonucleotides (ASOs), which are synthetic genetic strands used to regulate protein production.
These platforms are anchored by deep genetic understandings of the brain's circuitry. Management claims the approach creates an efficient path to proof-of-concept by using novel transgenic animal models and electrophysiology markers to predict human efficacy early in the development cycle.
What growth costs
It reported net losses of $303.3 million and $182.8 million for 2025 and 2024 while funding its Cerebrum and Solidus clinical pipelines.
The company is structurally required to reinvest heavily in research and development to advance its multimodal portfolio. As of December 31, 2025, it had reached an accumulated deficit of $1.1 billion due to the high costs of registrational clinical trials and discovery efforts.
Spending is currently focused on the Essential3 program for ulixacaltamide, the ENERGY program for vormatrigine, and the EMBRAVE3 Phase 3 study for elsunersen. Maintaining these programs requires substantial upfront capital for clinical research organizations, personnel, and commercial readiness activities.
What could damage it
Failure of the ulixacaltamide or relutrigine NDA submissions would eliminate the company's only current paths to commercializing its lead Cerebrum platform programs.
The company's viability is tied to a causal chain of regulatory approvals. If the FDA rejects the submitted NDAs or requires additional unexpected clinical trials, the company may be unable to raise the additional capital needed to continue operations.
Biopharmaceutical development is highly speculative; even with positive topline results, a product may fail to gain regulatory approval or prove commercially unviable. Failure in these lead programs would likely force a reduction or elimination of earlier-stage discovery efforts in the Solidus platform.
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and research collaboration and license agreement to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.